- 专利标题: Use of equol for treating androgen mediated diseases
-
申请号: US14810117申请日: 2015-07-27
-
公开(公告)号: US09408825B2公开(公告)日: 2016-08-09
- 发明人: Edwin Douglas Lephart , Trent D. Lund , Robert J. Handa
- 申请人: Edwin Douglas Lephart , Trent D. Lund , Robert J. Handa
- 申请人地址: US UT Provo US CO Fort Collins
- 专利权人: BRIGHAM YOUNG UNIVERSITY,COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
- 当前专利权人: BRIGHAM YOUNG UNIVERSITY,COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
- 当前专利权人地址: US UT Provo US CO Fort Collins
- 代理机构: Brinks Gilson & Lione
- 主分类号: A61K31/352
- IPC分类号: A61K31/352 ; A23L1/30 ; A61K31/35 ; A61K31/353
摘要:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
公开/授权文献
- US20150342924A1 USE OF EQUOL FOR TREATING ANDROGEN MEDIATED DISEASES 公开/授权日:2015-12-03
信息查询